JP2003513917A5 - - Google Patents

Download PDF

Info

Publication number
JP2003513917A5
JP2003513917A5 JP2001536138A JP2001536138A JP2003513917A5 JP 2003513917 A5 JP2003513917 A5 JP 2003513917A5 JP 2001536138 A JP2001536138 A JP 2001536138A JP 2001536138 A JP2001536138 A JP 2001536138A JP 2003513917 A5 JP2003513917 A5 JP 2003513917A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001536138A
Other languages
Japanese (ja)
Other versions
JP2003513917A (ja
Filing date
Publication date
Priority claimed from US09/435,470 external-priority patent/US6184248B1/en
Application filed filed Critical
Publication of JP2003513917A publication Critical patent/JP2003513917A/ja
Publication of JP2003513917A5 publication Critical patent/JP2003513917A5/ja
Pending legal-status Critical Current

Links

JP2001536138A 1999-11-08 2000-11-08 神経障害および神経変性疾患の治療のための組成物および方法 Pending JP2003513917A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/435,470 US6184248B1 (en) 1996-09-05 1999-11-08 Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US09/435,470 1999-11-08
PCT/US2000/030663 WO2001034138A1 (en) 1999-11-08 2000-11-08 Compositions and methods for treatment of neurological disorders and neurodegenerative diseases

Publications (2)

Publication Number Publication Date
JP2003513917A JP2003513917A (ja) 2003-04-15
JP2003513917A5 true JP2003513917A5 (zh) 2005-11-17

Family

ID=23728546

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001536138A Pending JP2003513917A (ja) 1999-11-08 2000-11-08 神経障害および神経変性疾患の治療のための組成物および方法

Country Status (6)

Country Link
US (2) US6184248B1 (zh)
EP (1) EP1242063A1 (zh)
JP (1) JP2003513917A (zh)
AU (1) AU1474001A (zh)
CA (1) CA2390655A1 (zh)
WO (1) WO2001034138A1 (zh)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100396171B1 (ko) * 1998-08-10 2003-08-27 아사히 가세이 가부시키가이샤 염산 파수딜의 경구 서방성 제제
JP2003530432A (ja) * 2000-04-12 2003-10-14 ミナーヴァ・バイオテクノロジーズ・コーポレーション 神経変性疾患の治療
EP1284729A4 (en) * 2000-04-13 2007-12-19 Mayo Foundation REDUCTION AGENTS OF A (BETA) 42
US20060004086A1 (en) * 2000-04-13 2006-01-05 Mayo Foundation For Medical Education And Research Method of reducing Abeta42 and treating diseases
US6812248B2 (en) * 2000-07-05 2004-11-02 John Hopkins University School Of Medicine Prevention and treatment of degenerative diseases by glutathione and phase II detoxification enzymes
US7625951B2 (en) * 2000-07-13 2009-12-01 University Of Kentucky Research Foundation Stimuli-responsive hydrogel microdomes integrated with genetically engineered proteins for high-throughput screening of pharmaceuticals
US20020173511A1 (en) * 2000-11-08 2002-11-21 Wurtman Richard J. Serotonergic compositions and methods for treatment of mild cognitive impairment
US8080637B1 (en) * 2001-07-20 2011-12-20 Kotwal Bioconsulting, LLC Therapeutic method of treating brain trauma in rodents with VCP
EP1450819A4 (en) * 2001-11-02 2008-01-23 Univ California METHODS AND COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISEASE, AUTOIMMUNE DISEASE AND GRAFT REJECTION
AU2003222020B2 (en) 2002-03-20 2008-08-28 University Of Maryland Baltimore A non-selective cation channel in neural cells and methods for treating brain swelling
US8980952B2 (en) * 2002-03-20 2015-03-17 University Of Maryland, Baltimore Methods for treating brain swelling with a compound that blocks a non-selective cation channel
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
EP1558268A4 (en) * 2002-09-17 2008-09-17 Univ New York METHODS FOR TREATING AGE-RELATED MEMORY ALTERATIONS (AAMI), LIGHT COGNITIVE DEFICITS (MCI) AND DEMENTIA USING CELL CYCLE INHIBITORS
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US20040141947A1 (en) * 2002-10-16 2004-07-22 Hunter Samuel F. Method for treatment of demyelinating central nervous system disease
US7524515B2 (en) * 2003-01-10 2009-04-28 Mutual Pharmaceuticals, Inc. Pharmaceutical safety dosage forms
EP1603548A4 (en) * 2003-02-05 2007-10-10 Myriad Genetics Inc COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
US7517519B2 (en) * 2003-02-06 2009-04-14 Cipla Limited Topical immunotherapy and compositions for use therein
WO2004093816A2 (en) * 2003-04-22 2004-11-04 Pharmacia Corporation Compositions comprising a selective cox-2 inhibitor and a calcium modulating agent
AT413944B (de) * 2003-05-27 2006-07-15 Binder Eva Dkfm Verwendung von oxicam-verbindungen
EP2236131A3 (en) * 2003-07-01 2011-03-02 President and Fellows of Harvard College Sirt1 modulators for manipulating cell/organism lifespan/stress response
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
US20050101597A1 (en) * 2003-07-10 2005-05-12 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitior and a non-NMDA glutamate modulator for the treatment of central nervous system damage
EP1651195A4 (en) * 2003-07-11 2007-10-03 Myriad Genetics Inc PHARMACEUTICAL PROCESSES, DOSIERSCHEMATA AND DOSAGE FORMS FOR THE TREATMENT OF ALZHEIMER DISEASE
US20050192321A1 (en) * 2003-09-15 2005-09-01 Meythaler Jay M. Treatment of neuropathy with rapid release aminopyridine
US20050113434A1 (en) * 2003-10-03 2005-05-26 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor administered under hypothermic conditions for the treatment of ischemic mediated central nervous system disorders or injury
US20050158376A1 (en) * 2003-10-23 2005-07-21 Sardi William F. Dietary supplement and method of processing same
US20090169585A1 (en) * 2003-10-23 2009-07-02 Resveratrol Partners, Llc Resveratrol-Containing Compositions And Their Use In Modulating Gene Product Concentration Or Activity
US7923448B2 (en) * 2003-11-03 2011-04-12 Cornell Research Foundation, Inc. Purine receptor inhibition as a therapeutic strategy in spinal cord and brain
WO2005046615A2 (en) * 2003-11-12 2005-05-26 Pharmacia & Upjohn Company Llc Compositions for treatment of central nervous system mediated disorders
EP1708689A2 (en) 2003-12-29 2006-10-11 The President and Fellows of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US20090155903A1 (en) * 2004-03-19 2009-06-18 Myriad Genetics, Incorporated Pharmaceutical composition and method
WO2005099761A1 (en) * 2004-04-07 2005-10-27 Resveratrol Partners, Llc Dietary supplement and method of processing same
US20070293538A1 (en) * 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
EP1745180A1 (en) * 2004-04-29 2007-01-24 Keystone Retaining Wall Systems, Inc. Veneers for walls, retaining walls and the like
WO2006007411A2 (en) * 2004-06-16 2006-01-19 President And Fellows Of Harvard College Methods and compositions for modulating bax-mediated apoptosis
US20060014705A1 (en) * 2004-06-30 2006-01-19 Howitz Konrad T Compositions and methods for selectively activating human sirtuins
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
WO2006020852A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
CA2618985A1 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
WO2006020850A2 (en) * 2004-08-11 2006-02-23 Myriad Genetics, Inc. Pharmaceutical composition and method for treating neurodegenerative disorders
US9629838B2 (en) 2004-09-16 2017-04-25 Morehouse School Of Medicine Composition for reducing nervous system injury and method of making and use thereof
AU2005287090A1 (en) 2004-09-18 2006-03-30 Department Of Veterans Affairs Therapeutic agents targeting the NCca-ATP channel and methods of use thereof
ATE486606T1 (de) * 2004-09-18 2010-11-15 Univ Maryland Therapeutische mittel zum targeting des ncca-atp- kanals und verwendungsverfahren dafür
US20060154980A1 (en) * 2005-01-11 2006-07-13 Finley John W Improved cox-2 inhibitory compositions and therapeutic regimen
CA2595159A1 (en) * 2005-01-13 2006-07-20 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
BRPI0613611A2 (pt) * 2005-07-22 2011-01-18 Myriad Genetics Inc formulações de alta concentração de fármaco e formas de dosagens
US20070021421A1 (en) * 2005-07-25 2007-01-25 Hampton Thomas G Measurement of gait dynamics and use of beta-blockers to detect, prognose, prevent and treat amyotrophic lateral sclerosis
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
EP2046119A2 (en) * 2006-07-07 2009-04-15 Myriad Genetics, Inc. Treatment of psychiatric disorders
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
GB0620685D0 (en) * 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
CA2674949A1 (en) 2007-01-12 2008-07-24 J. Marc Simard Targeting ncca-atp channel for organ protection following ischemic episode
US9533938B2 (en) 2007-01-31 2017-01-03 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
US11696908B2 (en) 2007-01-31 2023-07-11 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
US9636317B2 (en) 2007-01-31 2017-05-02 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters
ES2584327T3 (es) 2007-01-31 2016-09-27 Biosuccess Biotech Company Composiciones y métodos de uso de ésteres de forbol
US9974764B2 (en) 2007-01-31 2018-05-22 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
US10369222B2 (en) 2012-01-18 2019-08-06 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters for the treatment of stroke
US11564901B2 (en) 2007-01-31 2023-01-31 Biosuccess Biotech Co., Ltd. Compositions and methods of use of phorbol esters
US20100092469A1 (en) * 2007-02-09 2010-04-15 Simard J Marc Antagonists of a non-selective cation channel in neural cells
GB0702972D0 (en) * 2007-02-15 2007-03-28 Cambridge Entpr Ltd Induction of autography
CA2691199C (en) 2007-06-22 2017-09-12 Marc J. Simard Inhibitors of ncca-atp channels for therapy
WO2009104556A1 (ja) * 2008-02-19 2009-08-27 株式会社岐阜セラツク製造所 組成物
US20110023152A1 (en) * 2008-12-04 2011-01-27 Sigma-Aldrich Co. Genome editing of cognition related genes in animals
GB0911888D0 (en) * 2009-07-08 2009-08-19 Oxford Biodynamics Ltd Method of treating age related disorders
US20110086914A1 (en) * 2009-10-13 2011-04-14 Bailes Julian E Methods for Treating Traumatic Brain Injury
WO2013074948A1 (en) 2011-11-16 2013-05-23 Resveratrol Partners, Llc Compositions containing resveratrol and nucleotides
US9550722B2 (en) 2012-01-18 2017-01-24 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbal esters for the treatment of stroke
CN108969514A (zh) * 2012-01-18 2018-12-11 华鸿新药公司 佛波醇酯的组合物和使用方法
US10099996B2 (en) 2012-01-18 2018-10-16 Biosuccess Biotech Co. Ltd. Compositions and methods of use of phorbol esters in the treatment of neoplasms
WO2014200356A1 (en) 2013-06-13 2014-12-18 Smartfish As A marine oil formulation comprising reservatrol or derivatives thereof for use in treating, delaying and/or preventing alzheimer's desease
EP2818177A1 (en) 2013-06-24 2014-12-31 Celica, D.O.O. Mechanism and drug targets for reducing cell edema (neuroprotection) and cytoplasmic excitability in astrocytes in normal and pathological states
US10603316B2 (en) 2013-08-21 2020-03-31 Morehouse School Of Medicine Composition and methods for preventing or reducing the incidence of transient ischemic attacks
CN110742891B (zh) * 2013-08-21 2024-04-05 莫尔豪斯医学院 用于减轻神经系统损伤的组合物及该组合物的制造方法和用途
MA40904A (fr) * 2014-11-03 2017-09-12 Hygeia Tech Inc Compositions d'ester de phorbol et procédés pour traiter ou réduire la durée d'une cytopénie
US11103465B2 (en) 2017-11-22 2021-08-31 Ted's Brain Science, Inc. Trans-resveratrol topical medication for the treatment of pain and method of manufacture thereof
JP2018138592A (ja) * 2018-05-08 2018-09-06 モアハウス スクール オブ メディスンＭｏｒｅｈｏｕｓｅ Ｓｃｈｏｏｌ Ｏｆ Ｍｅｄｉｃｉｎｅ 神経系損傷を減少させるための組成物及びその製造方法及び使用
JP2020079289A (ja) * 2020-02-07 2020-05-28 モアハウス スクール オブ メディスンＭｏｒｅｈｏｕｓｅ Ｓｃｈｏｏｌ Ｏｆ Ｍｅｄｉｃｉｎｅ 神経系損傷を減少させるための組成物及びその製造方法及び使用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4791099A (en) * 1984-10-29 1988-12-13 Chaovanee Aroonsakul Method of treatment for central nervous system diseases such as Alzheimer's's disease
US5385915A (en) * 1990-05-16 1995-01-31 The Rockefeller University Treatment of amyloidosis associated with Alzheimer disease using modulators of protein phosphorylation
US5242932A (en) * 1991-12-17 1993-09-07 The Rockefeller University Treatment of amyloidosis associated with alzheimer disease
US5192753A (en) 1991-04-23 1993-03-09 Mcgeer Patrick L Anti-rheumatoid arthritic drugs in the treatment of dementia
GB9420616D0 (en) * 1994-10-12 1994-11-30 Merck Sharp & Dohme Method, compositions and use
US5840746A (en) * 1993-06-24 1998-11-24 Merck Frosst Canada, Inc. Use of inhibitors of cyclooxygenase in the treatment of neurodegenerative diseases
US5614649A (en) * 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
AU753657B2 (en) * 1997-10-22 2002-10-24 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and cerebrovascular disease
CA2322824A1 (en) * 1998-03-13 1999-09-16 Merck & Co., Inc. Combination therapy and composition for acute coronary ischemic syndrome and related conditions
AU4084599A (en) * 1998-05-18 1999-12-06 Oklahoma Medical Research Foundation Resveratrol inhibition of myeloperoxidase
DE19827387A1 (de) * 1998-06-19 1999-12-23 Bayer Ag Verwendung von Liganden einerDFP-Bindungsstelle zur Behandlung von ZNS-Krankheiten

Similar Documents

Publication Publication Date Title
BE2016C018I2 (zh)
BE2011C041I2 (zh)
JP2000228563A5 (zh)
JP2002535779A5 (zh)
AU2000236815A8 (zh)
JP2003513917A5 (zh)
JP2003518266A5 (zh)
JP2003509544A5 (zh)
JP2001036019A5 (zh)
JP2001276420A5 (zh)
FR15C0059I1 (zh)
JP2003509160A5 (zh)
JP2002536793A5 (zh)
JP2002029408A5 (zh)
JP2001262502A5 (zh)
JP2003518577A5 (zh)
JP2002160128A5 (zh)
JP2002166573A5 (zh)
JP2002150481A5 (zh)
JP2001232007A5 (zh)
JP2001052120A5 (zh)
JP2002187618A5 (zh)
BRPI0000763B8 (zh)
JP2002138343A5 (zh)
JP2002083755A5 (zh)